Statement Of Changes In Equity [Abstract]

Innate Pharma - Filing #2811003

Concept	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	495,000 EUR	—	—	51 901 EUR	329 323 EUR	7 570 EUR	—	—	—	—	—	384 255 EUR	—	4 044 EUR	54 151 EUR	—	—	819,000 EUR	—	58 103 EUR	—	—	—	379 637 EUR	272 213 EUR	4 011 EUR	—	—	219 404 EUR	107 440 EUR	52 809 EUR	456,000 EUR	375 220 EUR	3 978 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	—	7 570 EUR	— EUR	—	—	—	7 570 EUR	— EUR	— EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	58 103 EUR	—	— EUR	—	58 103 EUR	— EUR	— EUR	—	—	—	— EUR	— EUR	—	—	—	—	—	—
Other comprehensive income	—	670,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	362,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Comprehensive income	—	6 900 EUR	324,000 EUR	—	—	—	7 570 EUR	994,000 EUR	— EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	57 741 EUR	—	— EUR	—	58 103 EUR	— EUR	— EUR	—	—	—	362,000 EUR	— EUR	—	—	—	—	—	—
Issue of equity	—	— EUR	— EUR	—	—	—	— EUR	— EUR	— EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	— EUR	—	— EUR	—	— EUR	— EUR	— EUR	—	—	—	— EUR	— EUR	—	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	—	4 256 EUR	— EUR	—	—	—	—	—	4 256 EUR	— EUR	— EUR	—	— EUR	—	—	— EUR	4 249 EUR	—	—	—	—	— EUR	— EUR	—	—	—	—	4 249 EUR	—	—	—	—	—	—